European Commission approves Alecensa as first targeted adjuvant treatment for ALK-positive early-stage lung cancer.

The European Commission has approved Roche's Alecensa as the first targeted adjuvant treatment for ALK-positive early-stage lung cancer. This addresses an unmet need, as about half of patients experience disease recurrence post-surgery despite adjuvant chemotherapy. Alecensa showed a 76% risk reduction in disease recurrence or death for ALK-positive NSCLC patients in the Phase III ALINA study.